BMY Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Relaunch Into Neuroscience With Cobenfy Will Diversify Future Drug Portfolio
Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Bristol-Myers Squibb Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$60.02 |
| 52 Week High | US$63.33 |
| 52 Week Low | US$39.35 |
| Beta | 0.44 |
| 1 Month Change | 0.67% |
| 3 Month Change | 7.06% |
| 1 Year Change | 10.68% |
| 3 Year Change | -18.69% |
| 5 Year Change | 8.09% |
| Change since IPO | 2,708.98% |
Recent News & Updates
Recent updates
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
Mar 25Bristol-Myers Squibb: Why I'm Still Bullish
Mar 18Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Feb 21Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Feb 07Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Jan 31Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62
Dec 29
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Dec 20Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year
Dec 15Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)
Nov 275 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Nov 25Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Oct 28Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Oct 06Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Sep 27Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows
Sep 06Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues
Aug 15Bristol-Myers Squibb: A Potential Comeback In Healthcare
Aug 06Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Jul 27Bristol Myers Squibb: The More It Drops, The More I Buy
Jul 16Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?
Jun 13Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
Jun 09Shareholder Returns
| BMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.7% | -2.0% | -1.7% |
| 1Y | 10.7% | -3.2% | 5.6% |
Return vs Industry: BMY exceeded the US Pharmaceuticals industry which returned -3.2% over the past year.
Return vs Market: BMY exceeded the US Market which returned 5.6% over the past year.
Price Volatility
| BMY volatility | |
|---|---|
| BMY Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: BMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
| BMY fundamental statistics | |
|---|---|
| Market cap | US$121.80b |
| Earnings (TTM) | -US$8.95b |
| Revenue (TTM) | US$48.30b |
2.5x
P/S Ratio-13.6x
P/E RatioIs BMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMY income statement (TTM) | |
|---|---|
| Revenue | US$48.30b |
| Cost of Revenue | US$11.95b |
| Gross Profit | US$36.35b |
| Other Expenses | US$45.30b |
| Earnings | -US$8.95b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | -4.41 |
| Gross Margin | 75.26% |
| Net Profit Margin | -18.53% |
| Debt/Equity Ratio | 303.3% |
How did BMY perform over the long term?
See historical performance and comparisonDividends
4.1%
Current Dividend Yield-55%
Payout RatioDoes BMY pay a reliable dividends?
See BMY dividend history and benchmarks| Bristol-Myers Squibb dividend dates | |
|---|---|
| Ex Dividend Date | Apr 04 2025 |
| Dividend Pay Date | May 01 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 32 days |
Does BMY pay a reliable dividends?
See BMY dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/30 07:10 |
| End of Day Share Price | 2025/03/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bristol-Myers Squibb Company is covered by 44 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |